StemCell Therapy

DetailsCategory: AntibodiesPublished on Thursday, 09 January 2020 19:01Hits: 627

ACE1702 is a potential off-the-shelf cell therapy developed using Acepodias Antibody-Cell Conjugation technology

SAN FRANCISCO, CA, USA and TAIPEI, Taiwan I January 09, 2020 I Acepodia, a biotechnology company developing cancer immunotherapy based on its novel ACC (Antibody Cell-Conjugation) technology platform, today announced it has received clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate a Phase 1 clinical study of its natural killer (NK) cell therapy and lead drug candidate ACE1702 in patients with HER2-expressing solid tumors.

The FDAs clearance of our IND for ACE1702 is a major milestone for Acepodia that represents an important initial validation of our ACC platform, which can link any antibody, including those that have already proven effective in targeting tumors, to proprietary off-the-shelf natural killer cell line (oNK cells) without the need for genetic engineering, said Sonny Hsiao, Ph.D., chief executive officer of Acepodia, and the inventor of ACC while at University of California, Berkeley. This novel approach allows us to circumvent the complexity and the limitations associated with CAR-T and traditional NK based cell therapies. ACC significantly improves manufacturing costs and has the potential to generate a cost-effective cancer treatment that can deliver increased benefit to patients. We look forward to advancing ACE1702 into its first clinical trial.

About ACE1702ACE1702 is Acepodias lead clinical product candidate developed from the Companys proprietary ACC platform. It targets human HER2-expressing solidtumors using anti-HER2 antibody conjugated oNK cells. ACE1702 has demonstrated enhanced tumor cellkilling activities both in vitro and in vivo, while maintaining a favorable safety profile in GLPtoxicology studies. In preclinical studies, ACE1702 has shown enhanced tumor-killing activities against HER2 IHC 1+, 2+ and 3+ human cancer cells.

About Acepodia Acepodia is a privately held US-Taiwan biotechnology company committed to developing safe, effective, and affordable immunotherapeutic medicines targeting diseases with significant unmet medical needs, with a primary focus on oncology. Acepodias proprietary ACC (Antibody Cell-Conjugation) technology platform links tumor targeting antibodies to the surface of a novel and proprietary human NK cell line that have been specifically selected for their potent antitumor activity. The ACC technology can be seamlessly combined with currently available antibodies allowing for the rapid development of new targeted therapies in multiple indications, without the need for genetic engineering.

SOURCE: Acepodia

Read more here:
Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors |...

This entry was posted on January 11, 2020 at 5:49 pm and is filed under Genetic Engineering. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |